Belkin Vision has been awarded the CE Mark for Europe’s first and only automated, noncontact glaucoma laser treatment, the company announced. The company said it will begin controlled roll-out of the Eagle direct selective laser trabeculoplasty (DSLT) platform in Europe in the second half of 2022.

“The health economic impact of DSLT technology is potentially significant and is anticipated to allow for greater access to high-quality, contactless glaucoma treatment across Europe,” said Professor Sir Peng Tee Khaw, FRCS(Eng), FRCOphth, of Moorfields Eye Hospital and UCL, London, and a member of the Belkin scientific advisory board. “Current treatment options are more complex and DSLT can change the first-line glaucoma treatment paradigm improving patient quality of life, while at the same time improving access and allowing us to contribute to lower healthcare costs for both patients and health systems,” he added.

Belkin’s DSLT technology is automated, reducing the need for specialized training and making the laser more accessible. The company received $20M of blended financing in grants and equity from the European Innovation Council Accelerator that will support commercialization. The Israel-based medical device company stated that it “anticipates that its DSLT technology will become the new standard of first-line glaucoma care.”